Not sure you'd consider this company a true biotech as much as they would like for you to. They sell Methotrexate, a drug developed in the late-40's. Effective for a number of issues, but nowhere near a 1st-line prooduct in any disease state. Ixinity is their recent acquisition, but it is the joke of the Hemophilia-B marketplace, akin to a gnat on the backside of a rhinoceros. It may try to bite, but won't penetrate the thick hide of Pfizer, NovoNordisk, or Takeda. In 5 years, they have achieved a very impressive 3% share through lackluster marketing.